EU CHMP recommends approval of Fiasp (rapid acting insulin aspart) for diabetes in adults- Novo Nordisk

The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Fiasp (rapid acting insulin aspart), from Novo Nordisk, for the treatment of diabetes in adults. The applicant for this medicinal product is Novo Nordisk A/S. Fiasp will be available as a solution for injection (100 units/ml).

The active substance of Fiasp is insulin aspart, a fast-acting insulin analogue which is absorbed more rapidly by the body and can therefore act faster than human insulin. The replacement insulin acts in the same way as naturally produced insulin; it works by facilitating uptake of glucose into skeletal muscle and fat tissue, and by inhibiting glucose output from the liver. The benefits with Fiasp are its ability to control blood glucose. The most common side effect is hypoglycemia.